Our Short Oligonucleotide Synthesis Services support research teams, biotechnology companies, CROs, academic laboratories, and assay developers that need sequence-defined DNA or RNA oligos for primers, probes, adapters, controls, capture reagents, and other molecular biology workflows. Short oligonucleotides are commonly produced by solid-phase phosphoramidite chemistry, where iterative detritylation, coupling, capping, and oxidation steps build the sequence from the solid support. Project success depends not only on sequence length, but also on base composition, modification placement, purification requirements, delivered amount, and downstream assay conditions.
Our platform combines sequence feasibility review, custom DNA and RNA synthesis, modification planning, purification selection, analytical verification, tube or plate formatting, and technical documentation. We help customers define fit-for-purpose specifications before synthesis so that purity, yield, labeling, concentration, and packaging decisions match the actual experimental need rather than relying on a one-size-fits-all oligo format.
Fig 1. Synthesis of short oligo. (Jadhav et al., 2012)
Full-Length Product Control: Each coupling step can generate a small amount of truncated material, and the proportion of deletion products generally becomes more important as sequence complexity increases. We review length, GC content, homopolymers, repeats, and secondary-structure risk to select an appropriate synthesis and purification plan.
Purity Versus Recovery: Desalting, cartridge cleanup, HPLC, and PAGE do not serve the same purpose. Higher-resolution purification may improve removal of failure sequences or label-related impurities, but it can also reduce recovered material. We help customers choose a method according to assay sensitivity, oligo length, modification type, and required delivered amount.
Modification Compatibility: Fluorophores, quenchers, biotin, phosphorylation, amino groups, spacers, modified bases, and backbone changes can affect coupling, deprotection, hydrophobicity, purification, and storage. Our technical review considers modification position and chemistry before production to reduce avoidable redesign.
Scale and Delivered Yield: Synthesis scale describes the starting capacity of the synthesis, not the final amount recovered after cleavage, deprotection, purification, drying, and quality review. We align requested scale with the customer's concentration, reaction count, repeat-order, and format requirements.
Sequence-Dependent Behavior: GC-rich motifs, long homopolymers, self-complementary regions, repeated bases, and mixed DNA/RNA chemistries can complicate synthesis or downstream handling. Feasibility feedback allows difficult sequences to be adjusted, split into alternatives, or processed using a more suitable strategy.
Ready-to-Use Delivery: High-throughput teams often need more than a dry oligo in a tube. We support project-defined tube or plate layout, concentration normalization, duplex preparation, buffer selection, aliquoting, and labeling so materials can enter the planned workflow with fewer manual preparation steps.
Our short oligo synthesis services cover routine and specialized DNA or RNA constructs for discovery research, assay development, sequencing workflows, synthetic biology, and biochemical studies. Each project is scoped around the sequence, chemistry, purification level, analytical package, amount, and delivery format needed by the customer.
Projects can be coordinated with broader oligonucleotide synthesis services when multiple oligo types, larger quantities, or downstream functionalization are required.
Short oligonucleotide synthesis should be specified according to the downstream workflow rather than sequence length alone. The matrix below highlights common project formats and the technical decisions that most strongly influence synthesis, purification, and delivery.
| Oligo Format | Common Research Use | Key Design Review | Processing Considerations | Typical Deliverables |
| Unmodified DNA Primer | PCR, sequencing, cloning, mutagenesis | Melting behavior, GC balance, primer-dimer risk, terminal bases | Desalting may suit routine use; higher purification may be selected for sensitive workflows | Dry or reconstituted oligo, sequence record, quantity information |
| Short RNA Oligo | RNA interaction, biochemical assays, control strands | Sequence stability, self-structure, mixed chemistry, handling needs | Deprotection and purification must be compatible with RNA chemistry and modifications | Single strand or duplex, buffer option, analytical package by scope |
| Labeled Probe | Fluorescence detection, hybridization, imaging, binding assays | Reporter/quencher pairing, attachment site, spacer need, target accessibility | HPLC or another high-resolution method is often considered for hydrophobic labels | Labeled oligo, modification map, identity and purity data as agreed |
| Duplex or Adapter | Library preparation, ligation, barcoding, enzyme studies | Strand stoichiometry, end chemistry, overhangs, index compatibility | Individual strand QC followed by controlled annealing and concentration setup | Separate strands or annealed duplex, plate map, concentration record |
| Functionalized Capture Oligo | Immobilization, pull-down, biosensor, target enrichment | Linker length, surface orientation, terminal handle, steric accessibility | Purification must separate unreacted handle or label-related species where relevant | Functionalized oligo, linker notation, application-oriented handling guidance |
| Degenerate Oligo | Primer diversity, exploratory libraries, mutagenesis | Mixed-base positions, total diversity, representation strategy | Heterogeneous composition affects analytical interpretation and purification selection | Degeneracy specification, mixture notation, quantity and format record |
Purification should be chosen by considering oligo length, modification type, downstream sensitivity, required recovery, and the impurities that must be controlled. Desalting removes salts and small-molecule synthesis by-products, while HPLC or PAGE may be used when stronger separation of full-length material from failure sequences or label-related impurities is needed.
| Method | Primary Purpose | Best-Fit Projects | Main Tradeoffs | Suggested QC Discussion |
| Desalting | Remove salts, protecting-group residues, and small organic contaminants | Routine short unmodified primers and screening oligos with moderate impurity tolerance | Limited removal of closely related truncation products | Quantity review; identity confirmation when required by the project |
| Cartridge / Reverse-Phase Cleanup | Enrich full-length material through trityl-dependent or hydrophobic retention | Short oligos needing greater cleanup than desalting without full preparative HPLC | Performance depends on sequence, trityl strategy, and modification chemistry | Purity assessment selected according to assay sensitivity |
| HPLC | Separate full-length product from truncated or chemically distinct species | Modified oligos, fluorescent probes, capture oligos, and sensitive assay reagents | Method selection is chemistry-dependent; purification can reduce final recovery | Chromatographic purity review plus identity analysis as agreed |
| PAGE | Separate oligonucleotides primarily by size at high resolution | Projects where close length variants require stronger discrimination | More handling and lower recovery may be relevant for some sequences | Purity and recovery expectations should be set before synthesis |
| Combined Methods | Address more than one impurity class using orthogonal separation | Multi-modified, highly sensitive, or analytically complex short oligos | Added process time, material loss, and cost must be justified by application need | Define target impurity profile, release tests, and minimum delivered amount |
Our workflow connects project requirements with sequence feasibility, chemistry execution, purification, analytical review, and delivery formatting. Each step is intended to reduce specification gaps that can otherwise lead to unsuitable purity, insufficient recovered material, incompatible modifications, or avoidable reordering.
We collect sequences, oligo type, intended use, modification positions, required amount, preferred format, buffer needs, and analytical expectations. This establishes the practical performance requirements before chemistry and pricing are finalized.
The sequence is assessed for GC-rich motifs, repeats, homopolymers, self-complementarity, mixed chemistry, and modification compatibility. Customers receive feedback on technical risks and, when useful, alternative configurations that may improve manufacturability or assay fit.
We confirm synthesis scale, purification method, QC package, concentration, tube or plate format, annealing needs, and documentation. This creates an agreed project specification that aligns technical and procurement expectations.
The short oligonucleotide is assembled using chemistry appropriate for DNA, RNA, mixed-backbone, or modified constructs. Cleavage and deprotection conditions are selected to release the oligo while preserving compatible functional groups.
The agreed cleanup or purification method is applied, followed by quantity determination and project-defined identity or purity analysis. Results are reviewed against the requested specification before final formatting.
Oligos are dried, reconstituted, normalized, annealed, aliquoted, or plated according to scope. The customer receives the sequence and modification record, quantity information, available analytical data, and technical support for handling or repeat-order planning.
Short oligonucleotides are simple to order only when the project specification is simple. Modified probes, mixed chemistries, high-throughput plates, sensitive assays, and difficult sequences require coordinated design, synthesis, purification, and documentation decisions. Our service is structured to help customers make those decisions before production.
Custom short DNA and RNA oligos are foundational reagents across molecular biology, genomics, synthetic biology, and biochemical research. The most appropriate sequence design and purification strategy depends on whether the oligo functions as a primer, probe, adapter, control, capture reagent, substrate, or modified research tool.
Whether your project requires routine primers, short RNA controls, labeled probes, sequencing adapters, degenerate oligos, plate-formatted sets, or multi-modified constructs, our team can help define a practical synthesis and delivery specification. Share the sequence list, intended application, modification positions, required amount, purification preference, and desired format so we can assess feasibility and recommend an appropriate project plan. Contact us to discuss your custom short oligonucleotide requirements.
They are essential as PCR primers, sequencing probes, and gene editing guides. Their applications also include microarray fabrication and diagnostic assay development.
Our standard products achieve >95% purity by HPLC analysis. We offer higher purification grades for demanding applications like cloning or modification.
Yes, we routinely incorporate fluorescent dyes, biotin, phosphorothioate bonds, and amino modifiers. Our experts can advise on optimal modification strategies.
We optimize synthesis using premium phosphoramidites and controlled synthesis conditions. This approach maintains >99% average stepwise yield for sequences up to 30 nt.
Loading ......
